NZ551603A - N-substituted piperidines and their use as pharmaceuticals - Google Patents

N-substituted piperidines and their use as pharmaceuticals

Info

Publication number
NZ551603A
NZ551603A NZ551603A NZ55160305A NZ551603A NZ 551603 A NZ551603 A NZ 551603A NZ 551603 A NZ551603 A NZ 551603A NZ 55160305 A NZ55160305 A NZ 55160305A NZ 551603 A NZ551603 A NZ 551603A
Authority
NZ
New Zealand
Prior art keywords
carboxamide
piperidine
sulfonyl
hydroxycyclohexyl
trans
Prior art date
Application number
NZ551603A
Other languages
English (en)
Inventor
Wenqing Yao
Meizhong Xu
Colin Zhang
Yanlong Li
Jincong Zhuo
Brian Metcalf
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35786661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ551603(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of NZ551603A publication Critical patent/NZ551603A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ551603A 2004-06-24 2005-06-23 N-substituted piperidines and their use as pharmaceuticals NZ551603A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58255704P 2004-06-24 2004-06-24
US61457004P 2004-09-30 2004-09-30
US68684005P 2005-06-02 2005-06-02
PCT/US2005/022307 WO2006012226A2 (en) 2004-06-24 2005-06-23 N-substituted piperidines and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
NZ551603A true NZ551603A (en) 2010-11-26

Family

ID=35786661

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ551603A NZ551603A (en) 2004-06-24 2005-06-23 N-substituted piperidines and their use as pharmaceuticals

Country Status (13)

Country Link
US (2) US8071624B2 (enExample)
EP (1) EP1758580A4 (enExample)
JP (1) JP2008504275A (enExample)
AU (1) AU2005267289A1 (enExample)
BR (1) BRPI0512535A (enExample)
CA (1) CA2570637A1 (enExample)
CR (1) CR8793A (enExample)
EA (1) EA200700117A1 (enExample)
EC (1) ECSP067114A (enExample)
IL (1) IL179520A0 (enExample)
MX (1) MXPA06014574A (enExample)
NZ (1) NZ551603A (enExample)
WO (1) WO2006012226A2 (enExample)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
AU2005267289A1 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
EP1768954A4 (en) * 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
JP2008504276A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
US20060009471A1 (en) * 2004-06-24 2006-01-12 Wenqing Yao Amido compounds and their use as pharmaceuticals
WO2006002350A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
JP2008504274A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
BRPI0514230A (pt) * 2004-08-10 2008-06-03 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
MX2007005527A (es) * 2004-11-10 2007-07-09 Incyte Corp Compuestos de lactama y sus usos como farmaceuticos.
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
JP2008520700A (ja) * 2004-11-18 2008-06-19 インサイト・コーポレイション １１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの阻害剤およびその使用方法
CN102816081A (zh) 2005-01-05 2012-12-12 雅培制药有限公司 11-β-羟甾类脱氢酶1型酶的抑制剂
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
BRPI0606256A2 (pt) 2005-01-05 2009-06-09 Abbott Lab inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos
MX2007008237A (es) * 2005-01-06 2007-08-17 Astrazeneca Ab Compuestos de piridina novedosos.
AU2006222372B8 (en) * 2005-03-03 2010-04-08 F. Hoffmann-La Roche Ag 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type II diabetes mellitus
EP1866298A2 (en) * 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2006113261A2 (en) * 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7820699B2 (en) 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
MX2008000470A (es) * 2005-07-13 2008-03-11 Astrazeneca Ab Analogos de piridina nuevos.
EP1931652A2 (en) * 2005-09-21 2008-06-18 Incyte Corporation Amido compounds and their use as pharmaceuticals
BRPI0619446A2 (pt) 2005-12-05 2011-10-04 Incyte Corp compostos de lactama, suas composições e método de modulação da atividade de 11bhsd1
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
TW200804341A (en) * 2006-01-31 2008-01-16 Incyte Corp Amido compounds and their use as pharmaceuticals
JP5099814B2 (ja) * 2006-02-02 2012-12-19 田辺三菱製薬株式会社 含窒素複素二環式化合物
EP1981848A2 (en) 2006-02-07 2008-10-22 Wyeth 11-beta hsd1 inhibitors
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070208001A1 (en) * 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EP2013163A1 (en) * 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2018378A2 (en) * 2006-05-17 2009-01-28 Incyte Corporation Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same
TW200808695A (en) * 2006-06-08 2008-02-16 Amgen Inc Benzamide derivatives and uses related thereto
TW200815426A (en) * 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
CN101511815A (zh) * 2006-07-04 2009-08-19 阿斯利康(瑞典)有限公司 新型吡啶类似物
CN101506193A (zh) * 2006-07-04 2009-08-12 阿斯利康(瑞典)有限公司 新吡啶类似物
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
EP2044024A4 (en) * 2006-07-04 2011-06-29 Astrazeneca Ab NEW ANALOGUES OF PYRIDINE
EP1918285A1 (en) 2006-11-03 2008-05-07 Merck Sante Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors
TW200833333A (en) * 2007-01-12 2008-08-16 Astrazeneca Ab New pyridine analogues
UY30868A1 (es) * 2007-01-12 2008-09-02 Astrazeneca Ab Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolas y aplicaciones.
TW200833335A (en) * 2007-01-12 2008-08-16 Astrazeneca Ab New pyridine analogues
JP5603770B2 (ja) * 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
CL2008001839A1 (es) * 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
TW200902513A (en) * 2007-07-13 2009-01-16 Astrazeneca Ab New pyridine analogues
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
CA2706991A1 (en) * 2007-11-30 2009-06-04 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituted piperidines
DE102008010221A1 (de) 2008-02-20 2009-08-27 Bayer Healthcare Ag Heteroaryl-substituierte Piperidine
DE102007057718A1 (de) 2007-11-30 2009-07-30 Bayer Healthcare Ag Heteroaryl-substituierte Piperidine
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2280705B1 (en) 2008-06-05 2014-10-08 Glaxo Group Limited Novel compounds
EP2280959B1 (en) 2008-06-05 2012-04-04 Glaxo Group Limited 4-amino-indazoles
JP5508400B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
BRPI0920881B1 (pt) * 2008-10-17 2021-09-21 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
DK2379525T3 (en) 2008-12-19 2015-10-19 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
DK2381778T3 (en) 2008-12-22 2016-09-12 Chemocentryx Inc C5aR antagonists
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
DE102009014484A1 (de) * 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
PE20120321A1 (es) 2009-04-30 2012-04-19 Glaxo Group Ltd Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022895A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022897A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
NZ599770A (en) 2009-12-17 2014-06-27 Boehringer Ingelheim Int New ccr2 receptor antagonists and uses thereof
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
DK2585064T3 (en) * 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
CA2814011A1 (en) * 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100719A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9399194B2 (en) * 2014-07-16 2016-07-26 Battelle Energy Alliance, Llc Methods for treating a liquid using draw solutions
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
BR112017012406A2 (pt) 2014-12-12 2018-07-31 Sanofi Aventis Deutschland formulação com relação fixa de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
BR112017028492B1 (pt) 2015-07-02 2023-12-26 Centrexion Therapeutics Corporation Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica
US20170202821A1 (en) 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CA3026784A1 (en) 2016-06-07 2017-12-14 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic pyrazine derivatives useful as shp2 inhibitors
MY200227A (en) 2017-03-23 2023-12-15 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (enExample) 1960-03-14
US3201466A (en) 1963-03-08 1965-08-17 Gulf Oil Corp Substituted cyclopropanecarboxanilide herbicides
US3849403A (en) 1968-04-29 1974-11-19 American Home Prod 2,3,4,5-tetrahydro-1,1,5,5-tetrasubstituted-1h-3-benzazepines
FR1600908A (en) 1968-11-14 1970-08-03 Hypocholesterolaemic and anorexigenic - phenoxy alkanoylaralkylamines
DE2114420A1 (de) 1971-03-25 1972-10-05 Merck Patent Gmbh, 6100 Darmstadt Substituierte Phenylalkanol-Derivate und Verfahren zu ihrer Herstellung
US3923350A (en) 1974-03-11 1975-12-02 Commercial Metals Company Precision bearing assembly
ES427013A1 (es) 1974-06-05 1976-07-16 Alter Sa Un procedimiento de preparacion de ciertas amidas del aci- do 2 - (p - clorofenoxi) - 2 - metilpropionico.
GB1460389A (en) 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
US3933829A (en) 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
TR18917A (tr) 1974-10-31 1977-12-09 Ciba Geigy Ag 1-(bis-triflormetilfenil)-2-oksopirolidin-4-karbonik asitleri ve bunlarin tuerevleri
US3933350A (en) * 1974-12-09 1976-01-20 Mignano Frank J Paper insert feeder
FR2312247A1 (fr) 1975-05-30 1976-12-24 Parcor Derives de la thieno-pyridine, leur procede de preparation et leurs applications
US4145435A (en) 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
JPS57156450A (en) 1981-03-24 1982-09-27 Ihara Chem Ind Co Ltd 1-(4-chlorophenyl)-1-cyclopentanecarboxylic acid derivative, its preparation, and aquatic life repellent containing said compound as active component
US4439606A (en) 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
CA1325217C (en) 1983-11-07 1993-12-14 John T. Lai 3,5-dialkyl-4-hydroxyphenyl-substituted derivatives
JPS60149562A (ja) 1984-01-13 1985-08-07 Kyorin Pharmaceut Co Ltd 新規なピペリジン誘導体およびその製法
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
FI874212L (fi) * 1986-09-29 1988-03-30 Bristol Myers Co Foerfarande foer framstaellning av 5-aryliden- och 5-alkylidensubstituerade hydantoiner.
EP0273659A1 (en) 1986-12-27 1988-07-06 Takeda Chemical Industries, Ltd. Azaspiro compounds, their production and use
DE3911670A1 (de) 1989-04-10 1990-10-11 Schaeffler Waelzlager Kg Radial-waelzlager
DE3920616A1 (de) 1989-06-23 1991-01-03 Boehringer Mannheim Gmbh Arzneimittel, enthaltend di-tert.-butylhydroxyphenyl-derivate sowie neue derivate
US5206240A (en) 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
FR2672213B1 (fr) 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
JPH04275271A (ja) 1991-03-04 1992-09-30 Lederle Japan Ltd インドメタシン誘導体
JPH04334357A (ja) 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
FR2678272B1 (fr) 1991-06-27 1994-01-14 Synthelabo Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2705343B1 (fr) 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
DE9403308U1 (de) 1994-02-28 1994-04-28 INA Wälzlager Schaeffler KG, 91074 Herzogenaurach Ausgleichsgetriebe für ein Kraftfahrzeug
FR2724656B1 (fr) 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR9509036A (pt) 1994-09-27 1997-10-14 Janssen Pharmaceutica Nv Derivados biciclicos de benzoato de peperidinila n-substituída
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US5693567A (en) 1995-06-07 1997-12-02 Xerox Corporation Separately etching insulating layer for contacts within array and for peripheral pads
FR2736053B1 (fr) 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
GB9517622D0 (en) 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
JPH11512723A (ja) 1995-09-29 1999-11-02 イーライ リリー アンド カンパニー フィブリノゲン依存血小板凝集抑制物質としてのスピロ化合物
GB9604311D0 (en) 1996-02-29 1996-05-01 Merck & Co Inc Inhibitors of farnesyl-protein transferase
GB9600235D0 (en) 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
DK0923555T3 (da) 1996-05-01 2005-08-15 Ortho Mcneil Pharm Inc pyrrolidin, piperidin og hexahydroazepin til behandling af trombotiske lidelser
NZ334389A (en) 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
CZ84199A3 (cs) * 1996-09-13 1999-11-17 Schering Corporation Nové, tricyklické piperidinylové sloučeniny použitelné jako inhibitory farnesylprotein transferasy
IL122072A (en) 1996-11-14 2001-03-19 Akzo Nobel Nv Piperidine derivatives their preparation and pharmaceutical compositions containing them
GB2327609A (en) * 1997-07-23 1999-02-03 Merck & Co Inc A method for eliciting an avß5 or dual avß3/avß5 antagonizing effect
EP1063230B1 (en) 1998-02-27 2003-04-23 Sankyo Company Limited Cyclic amino compounds
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
CA2336475A1 (en) 1998-07-02 2000-01-13 Christopher J. Dinsmore Inhibitors of prenyl-protein transferase
HUP0100819A3 (en) 1998-10-16 2002-12-28 Daiichi Asubio Pharma Co Ltd Aminophenoxyacetic acid derivatives as neuroprotectants and pharmaceutical compositions containing them
KR20010108394A (ko) 1999-03-26 2001-12-07 다비드 에 질레스 신규 화합물
AU4180900A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
ES2165274B1 (es) 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
DK1202994T3 (da) 1999-07-21 2004-08-02 Astrazeneca Ab Nye forbindelser
JP4275271B2 (ja) 1999-11-15 2009-06-10 寺崎電気産業株式会社 計測表示装置
RU2265021C2 (ru) 1999-12-03 2005-11-27 Оно Фармасьютикал Ко., Лтд. Производные триазаспиро[5,5]ундекана (варианты), фармацевтическая композиция и способ регулирования хемокина/рецептора хемокина
PT1236726E (pt) 1999-12-03 2005-04-29 Ono Pharmaceutical Co Derivados de triazaespiro[5.5]undecano e farmacos que os contem como ingrediente activo
AP2002002664A0 (en) 2000-04-26 2002-12-31 Warner Lambert Co Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
AUPR079700A0 (en) * 2000-10-17 2000-11-09 Alchemia Pty Ltd Combinatorial libraries of monosaccharides
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US6547958B1 (en) 2001-07-13 2003-04-15 Chevron U.S.A. Inc. Hydrocarbon conversion using zeolite SSZ-59
US7074788B2 (en) 2001-11-22 2006-07-11 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
ES2246481T3 (es) * 2002-02-27 2006-02-16 Pfizer Products Inc. Inhibidores de la acc.
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
CA2488972A1 (en) 2002-06-19 2003-12-31 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
WO2004018479A1 (en) 2002-08-21 2004-03-04 Astrazeneca Ab Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
AU2003263323A1 (en) 2002-09-07 2004-03-29 Celltech R And D Limited Quinazolinone derivatives
US20040072802A1 (en) 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
ATE422203T1 (de) 2002-10-09 2009-02-15 Schering Corp Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden
WO2004033427A1 (en) 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
WO2004035581A1 (ja) 2002-10-18 2004-04-29 Ono Pharmaceutical Co., Ltd. スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
RU2333203C2 (ru) 2002-12-25 2008-09-10 Дайити Фармасьютикал Ко., Лтд. Диаминовые производные
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
WO2004076418A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US20040188324A1 (en) 2003-03-26 2004-09-30 Saleh Elomari Hydrocarbon conversion using molecular sieve SSZ-65
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
US7417152B2 (en) 2003-05-02 2008-08-26 Elan Pharmaceuticals, Inc. 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases
WO2004103995A1 (en) 2003-05-20 2004-12-02 Novartis Ag N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
SE0302755D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005047286A1 (ja) 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
CA2549651A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
CN1918156B (zh) 2003-12-22 2010-10-27 先灵公司 作为cxc-和cc-趋化因子受体配体的异噻唑二氧化物
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
EP1729755A1 (en) 2004-01-21 2006-12-13 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
EP1745019A1 (en) 2004-05-06 2007-01-24 Pfizer Inc. Novel compounds of proline and morpholine derivatives
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
US20060009471A1 (en) 2004-06-24 2006-01-12 Wenqing Yao Amido compounds and their use as pharmaceuticals
JP2008504274A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
AU2005267289A1 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
JP2008504276A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
WO2006002350A1 (en) 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
BRPI0514230A (pt) 2004-08-10 2008-06-03 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
WO2006047176A1 (en) 2004-10-22 2006-05-04 Cargill, Incorporated Process for the production of maltodextrins and maltodextrins
MX2007005527A (es) 2004-11-10 2007-07-09 Incyte Corp Compuestos de lactama y sus usos como farmaceuticos.
US7456194B2 (en) 2004-11-12 2008-11-25 Bristol-Myers Squibb Company Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
JP2008520700A (ja) 2004-11-18 2008-06-19 インサイト・コーポレイション １１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの阻害剤およびその使用方法
CN102816081A (zh) 2005-01-05 2012-12-12 雅培制药有限公司 11-β-羟甾类脱氢酶1型酶的抑制剂
AU2006222372B8 (en) 2005-03-03 2010-04-08 F. Hoffmann-La Roche Ag 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type II diabetes mellitus
EP1931652A2 (en) 2005-09-21 2008-06-18 Incyte Corporation Amido compounds and their use as pharmaceuticals
BRPI0619446A2 (pt) 2005-12-05 2011-10-04 Incyte Corp compostos de lactama, suas composições e método de modulação da atividade de 11bhsd1
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
TW200804341A (en) 2006-01-31 2008-01-16 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2007219880A (ja) * 2006-02-17 2007-08-30 Fujitsu Ltd 評判情報処理プログラム、方法及び装置
WO2007101270A1 (en) 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EP2013163A1 (en) 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
EP2018378A2 (en) 2006-05-17 2009-01-28 Incyte Corporation Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.

Also Published As

Publication number Publication date
US20120040964A1 (en) 2012-02-16
JP2008504275A (ja) 2008-02-14
EP1758580A4 (en) 2008-01-16
US8071624B2 (en) 2011-12-06
EA200700117A1 (ru) 2007-06-29
CA2570637A1 (en) 2006-02-02
CR8793A (es) 2007-08-28
MXPA06014574A (es) 2007-03-12
IL179520A0 (en) 2007-05-15
ECSP067114A (es) 2007-01-26
US8288417B2 (en) 2012-10-16
AU2005267289A1 (en) 2006-02-02
EP1758580A2 (en) 2007-03-07
WO2006012226A2 (en) 2006-02-02
WO2006012226A3 (en) 2006-07-27
BRPI0512535A (pt) 2008-03-25
US20060004049A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
US8288417B2 (en) N-substituted piperidines and their use as pharmaceuticals
US20060122197A1 (en) Amido compounds and their use as pharmaceuticals
US9957229B2 (en) Amido compounds and their use as pharmaceuticals
CA2585797C (en) Lactam compounds and their use as pharmaceuticals
US20050288317A1 (en) Amido compounds and their use as pharmaceuticals
US20070293529A1 (en) Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
US20050288338A1 (en) Amido compounds and their use as pharmaceuticals
US20070066584A1 (en) Amido compounds and their use as pharmaceuticals
US20060009471A1 (en) Amido compounds and their use as pharmaceuticals
CA2589565A1 (en) Amido compounds and their use as pharmaceuticals
EP1979318A1 (en) Amido compounds and their use as pharmaceuticals
CA2587153A1 (en) Inhibitors of 11-.beta. hydroxyl steroid dehydrogenase type 1 and methods of using the same
KR20070022792A (ko) Ｎ-치환된 피페리딘 및 이의 약제로서의 용도

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed